<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
PREMIER RESEARCH WORLDWIDE, LTD.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
740568 10 0
(CUSIP Number)
The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and a subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
(Continued on the following pages)
Page 1 of 4 Pages
<PAGE>
- -------------------------------
CUSIP NO. 740568 10 0
- -------------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. or I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON
Joel Morganroth, M.D. ###-##-####
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(See Instructions) (b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
495,175
NUMBER OF
SHARES ----------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY
EACH 9,600
REPORTING
PERSON ----------------------------------------------------
WITH 7 SOLE DISPOSITIVE POWER
495,175
----------------------------------------------------
8 SHARED DISPOSITIVE POWER
9,600
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,004,000 (disclaims beneficial ownership of 495,225 shares)
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (See Instructions)
[ ]
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
14.7%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (See Instructions)
IN
- --------------------------------------------------------------------------------
-2-
<PAGE>
Item 4: Ownership:
Item 4 of the Schedule 13G of Joel Morganroth, M.D. is hereby
amended to read in its entirety as follows:
As of August 31, 1999, Dr. Morganroth, as described more fully
below, may be deemed to own beneficially (as that term is defined in
Rule 13d-3 of the Securities Exchange Act of 1934, as amended)
1,004,000 shares of the common stock of Premier Research Worldwide,
Ltd., representing 14.7% of the outstanding shares of common stock. Dr.
Morganroth's beneficial ownership is as follows:
1. 495,175 shares directly owned by Dr. Morganroth,
as to which he has sole voting and dispositive
power.
2. 9,600 shares owned by a pension plan, as to
which Dr. Morganroth has shared voting and
dispositive power.
3. 4,000 shares underlying currently exercisable
options granted under a Corporation stock option
plan.
4. 495,225 shares held in a trust, the trustee of
which is Dr. Morganroth's wife and the
beneficiaries of which are Dr. Morganroth's
children. Dr. Morganroth disclaims beneficial
ownership of these shares.
-3-
<PAGE>
Signature
---------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in my statement is true, complete and
correct.
Dated: September 1, 1999
/s/ Joel Morganroth, M.D.
-------------------------
[Signature]
Joel Morganroth, M.D.
-------------------------
Name/Title
-4-
